Updated overall survival (OS) results from the phase 3 LAURA study “further substantiate the fact that osimertinib after definitive chemoradiotherapy is the new standard of care” for patients with unresectable stage III EGFR-mutated non–small cell lung cancer, study investigators said during a presentation today at the European Lung Cancer Congress 2025.

Suresh S. Ramalingam, MD, FACP, FASCO, of the Winship Cancer Institute at Emory University, presented the updated data on the EGFR tyrosine kinase inhibitor during the second proffered paper session of the congress, which was held in Paris, France.